@entity1582 is a major @entity1583 , with an incidence of over 20,000 new diagnoses in the United States each year. Historically, a lack of effective therapies led to a poor @entity1 prognosis. However, the introduction of new agents over the past decade has improved the treatment landscape for these @entity1 , resulting in improved responses and prolonged progression-free and overall survival. Unfortunately, though, nearly all @entity1582 @entity1 go on to experience @entity66 . The definition of this progression has also evolved with a growing understanding of the biology of @entity1582 as well how the disease responds to these newer agents. While refractory @entity1582 is considered to be a disease that does not respond to a particular therapy, the new definition of relapsed and refractory @entity1582 includes @entity1 who show disease progression within 60 days of discontinuing therapy. These new definitions are an important consideration when interpreting both previously reported and ongoing clinical trial data. Another major issue in the management of relapsed and refractory @entity1582 is how to treat @entity1 after they no longer respond to @entity2816 , @entity6985 , and @entity1749 . Regarding this issue, a number of novel agents are now in clinical trial development; many of them show indications of significant activity, even in heavily pretreated @entity1 . Thus, the introduction of these newer agents has the potential to again make a major impact on @entity1582 @entity1 outcomes.

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['relapsed disease'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'Multiple myeloma'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancy'] @entity6985 :: ('MESH:C467567', 'Chemical') :: ['lenalidomide'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
